StemCell Institute Inc.
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (14)
StemCell Institute Inc. owes ¥0.68 for every ¥1 it owns. Net profit fell 60% in the year to Mar 2026, and shrank 8% a year on average over 3 years.
Compared with Healthcare companies in Japan · latest annual results Mar 2026.
P/E ratio
48.6Investors pay ¥48.6 for every ¥1 of StemCell Institute Inc.'s yearly profit, higher than 90% of Healthcare companies in Japan.
P/B ratio
2.65The share price is 2.65 times StemCell Institute Inc.'s book value per share, higher than 75% of Healthcare companies in Japan.
Market cap
¥7.2 BThe total market value of all of StemCell Institute Inc.'s shares at today's price (share price × number of shares), smaller than 69% of Healthcare companies in Japan. PosiCap size class: Micro Cap.
Net worth (book value)
¥2.7 BWhat StemCell Institute Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
¥270.03Net worth divided by the number of shares. The share price of ¥716.00 is 2.7 times this, which is the P/B above.
Return on equity (ROE)
4.6%StemCell Institute Inc. earned 4.6% on its shareholders' money over the last year, lower than 64% of Healthcare companies in Japan.
Owes vs Owns
0.68×StemCell Institute Inc. owes ¥0.68 for every ¥1 it owns (moderate), higher than 83% of Healthcare companies in Japan.
Dividend yield
NoneStemCell Institute Inc. does not currently pay a dividend.
Revenue growth
+5%Revenue rose 5% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Profit growth
-60%Net profit fell 60% in the year to Mar 2026, and shrank 8% a year on average over 3 years.
Profit margin
5.5%StemCell Institute Inc. keeps ¥6 of every ¥100 of revenue as net profit.
Cash quality
0.5×Cash from StemCell Institute Inc.'s business was 0.5× its reported profit in the year to Mar 2026 — less cash came in than the profit reported.
Interest cover
37.2×StemCell Institute Inc.'s operating profit covered its interest costs 37.2 times in the year to Mar 2026.
Cash vs debt
Net cashStemCell Institute Inc. held ¥2.4 B more cash than debt (net cash) at Mar 2026.
Questions
What is StemCell Institute Inc.'s P/E ratio?
Investors pay ¥48.6 for every ¥1 of StemCell Institute Inc.'s yearly profit, higher than 90% of Healthcare companies in Japan.
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For StemCell Institute Inc.: ¥7.2 B ÷ ¥2.7 B (30 Jun 2026) = 2.7.
What is StemCell Institute Inc.'s return on equity?
StemCell Institute Inc. earned 4.6% on its shareholders' money over the last year, lower than 64% of Healthcare companies in Japan.
How much does StemCell Institute Inc. owe compared with what it owns?
StemCell Institute Inc. owes ¥0.68 for every ¥1 it owns (moderate), higher than 83% of Healthcare companies in Japan.
Does StemCell Institute Inc. pay a dividend?
No. StemCell Institute Inc. does not currently pay a dividend.
Is StemCell Institute Inc.'s revenue growing?
Revenue rose 5% in the year to Mar 2026, and grew 10% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.